HMGB1 and myeloid sarcoma: The significant role of HMGB1 in NMO inflammation and damage of astrocytes has been confirmed by Uzawa et al.; however, they reported that primarily increased levels of HMGB1 in CSF and serum of NMO patients (vs. MS) decreased after treatment [143].